Alirocumab

Comercialización: Praluent: Europa (EMA), EE.UU. (FDA)

Filtros

Temática: Ateroesclerosis Hipercolesterolemia Dislipidemia Síndrome Coronario Agudo Hiperlipidemia Otros
Estado: Completado Activo, no reclutando Reclutando Otros

Seleccione alguna de las opciones para acotar la búsqueda

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Estado: Completado

Clinical Trials Pubmed 1

Subanálisis Odyssey Outcomes

Diabetes Polivascular Mortalidad Ictus Según c-LDL alcanzado Eventos totales Hospitalizaciones Poligenético EAP y TEV Función renal Bypass coronario Lp(a) y eventos totales Lp(a) y cLDL nominalmente controlado Lp(a) y riesgo CV Tipo de IM Edad Intensidad de tratamiento con estatina Factores de riesgo metabólicos ApoB y riesgo residual IM previo Consecución de objetivos de las guías

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

Estado: Completado

Clinical Trials Pubmed 1 Pubmed 2

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

Estado: Completado

Clinical Trials Pubmed 1 Pubmed 2 Pubmed 3

Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Estado: Completado

Clinical Trials Pubmed 1

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Estado: Completado

Clinical Trials Pubmed 1

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Estado: Completado

Clinical Trials Pubmed 1

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

Estado: Completado

Clinical Trials Pubmed 1

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Estado: Completado

Clinical Trials Pubmed 1 Pubmed 2

Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy (ODYSSEY ESCAPE)

Estado: Completado

Clinical Trials Pubmed 1

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

Estado: Completado

Clinical Trials Pubmed 1

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

Estado: Completado

Clinical Trials Pubmed 1 Pubmed 2

Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) (ODYSSEY FH II)

Estado: Completado

Clinical Trials Pubmed 1

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia (ODYSSEY MONO)

Estado: Completado

Clinical Trials Pubmed 1

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

Estado: Completado

Clinical Trials Pubmed 1

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

Estado: Completado

Clinical Trials Pubmed 1

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (ODYSSEY FH I)

Estado: Completado

Clinical Trials Pubmed 1

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

Estado: Completado

Clinical Trials Pubmed 1

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Estado: Completado

Clinical Trials Pubmed 1 Pubmed 2 Pubmed 3

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (ODYSSEY KIDS)

Estado: Completado

Clinical Trials Pubmed 1

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Estado: Completado

Clinical Trials Pubmed 1

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Estado: Completado

Clinical Trials

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Estado: Activo, no reclutando

Clinical Trials

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (ODYSSEY HoFH)

Estado: Completado

Clinical Trials Pubmed 1